+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Europe Veterinary Vaccine Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4772037
  • Report
  • February 2019
  • Region: Europe
  • 74 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Ceva Sante Animale
  • Eli Lilly & Company
  • Hester Biosciences Ltd
  • HIPRA
  • Merck & Co. Inc.
  • Virbac SA
  • MORE
Market Overview

The European veterinary vaccine market is expected to witness a CAGR of 5.57% over the forecast period, 2019-2024. The key factors propelling the growth of this market are increasing incidences of livestock diseases, initiatives by various government agencies, animal associations, leading players in the European region, and the increasing incidences of zoonotic diseases.

In 2018, Boehringer Ingelheim announced its plans to invest EUR 65 million in France for the production of avian vaccines, as its demand increased with an increase in poultry consumption. Moreover, the Veterinary Vaccinology Network (VVN) is an association of the United Kingdom, which takes care of veterinary vaccines in the country. The VVN association is working to introduce new developments, along with the latest tools, and technologies to meet the needs of veterinary vaccinology in the country. Furthermore, in 2017, Spain implemented the Brucellosis Eradication Program with a target of reducing the number of cases of brucellosis at the end of 2018 and complete eradication by 2019.

The aforementioned statements indicate that veterinary health is an essential part for the European countries and good care of animal health is taken, which is a prime factor that augments the growth of the European veterinary vaccine market.

Scope of the Report

The European veterinary vaccine market has been segmented based on vaccine type, technology, and geography. By vaccine type, the market is divided into livestock vaccines and companion animal vaccines. By technology, the market is divided into live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and other technologies.

Key Market Trends

Live Attenuated Vaccines Segment is Expected to hold the Largest Market Share

The live attenuated vaccines segment of the European veterinary vaccine market is believed to have the largest market size, and it is expected to witness a CAGR of approximately 5.12% over the forecast period.

All vaccines licensed for oral or intranasal administration are attenuated. These vaccines must be stored and handled properly, with strict attention to temperature, even in the lyophilized (free-dried) state. After the reconstitution, the dose of the vaccine should be administered promptly (within 1 hour) or discarded. Some examples of these type of vaccines include canine distemper virus vaccines and all canine parvovirus and adenovirus-2 vaccines.

Owing to the rising use of live attenuated vaccines, the segment is contributing to the largest market share of the European veterinary vaccine market.

Competitive Landscape

The European veterinary vaccine market is a consolidated market, and it consists of several major players. In terms of market share, a few of the major players currently dominate the market. Companies, like Zoetis Inc., Merck & Co. Inc., Virbac, Eli Lily and Company (Elanco), and Boehringer Ingelheim International GmbH, hold the substantial market share in the European veterinary vaccine market.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ceva Sante Animale
  • Eli Lilly & Company
  • Hester Biosciences Ltd
  • HIPRA
  • Merck & Co. Inc.
  • Virbac SA
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidences of Livestock Diseases
4.2.2 Initiatives by Various Government Agencies, Animal Associations, and Leading Players
4.2.3 Increasing Incidences of Zoonotic Diseases
4.3 Market Restraints
4.3.1 High Storage Costs for Vaccines
4.3.2 Lack of Veterinarians and Shortage of Skilled Farms
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Animal Vaccine Type
5.1.1 Livestock Vaccines
5.1.1.1 Bovine Vaccines
5.1.1.2 Poultry Vaccines
5.1.1.3 Porcine Vaccines
5.1.1.4 Other Livestock Vaccines
5.1.2 Companion Animal Vaccines
5.1.2.1 Canine Vaccines
5.1.2.2 Feline Vaccines
5.1.2.3 Equine Vaccines
5.2 By Technology
5.2.1 Live Attenuated Vaccines
5.2.2 Inactivated Vaccines
5.2.3 Toxoid Vaccines
5.2.4 Recombinant Vaccines
5.2.5 Other Technologies
5.3 Geography
5.3.1 Europe
5.3.1.1 Germany
5.3.1.2 UK
5.3.1.3 France
5.3.1.4 Italy
5.3.1.5 Spain
5.3.1.6 Rest of Europe

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co. Inc.
6.1.2 Virbac SA
6.1.3 Hester Biosciences Ltd
6.1.4 Eli Lilly & Company
6.1.5 Ceva Sante Animale
6.1.6 Phibro Animal Health Corp.
6.1.7 HIPRA
6.1.8 Zoetis Inc.
6.1.9 Boehringer Ingelheim International GmbH

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Merck & Co. Inc.
  • Virbac SA
  • Hester Biosciences Ltd
  • Eli Lilly & Company
  • Ceva Sante Animale
  • Phibro Animal Health Corp.
  • HIPRA
  • Zoetis Inc.
  • Boehringer Ingelheim International GmbH
Note: Product cover images may vary from those shown
Adroll
adroll